CXCR4 and malignant colon neoplasm: In recent studies, we established that CXCR4 antagonist MSX-122 (substituted pyrimidine-2-amine) blocked CXCL12-induced EGFR transactivation and colon cancer progression in azoxymethane-induced mouse model [126].